Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2014

01-07-2014 | Research Article

Overexpression of HCC1/CAPERα may play a role in lung cancer carcinogenesis

Authors: Yurong Chai, Xinxin Liu, Liping Dai, Yang Li, Mei Liu, Jian-Ying Zhang

Published in: Tumor Biology | Issue 7/2014

Login to get access

Abstract

HCC1/CAPERα is considered to be a novel human tumor-associated antigen, and the tumor-specific immunity of HCC1/CAPERα has been reported in several types of cancer. However, there was very limited evidence indicating its function in tumorigenesis. In the present study, to elucidate the roles and underlying molecular mechanism of HCC1/CAPERα in lung cancer, we examined the expression of HCC1/CAPERα in human non-small cell lung cancer (NSCLC) cell line and NSCLC tissue microarray (TMA). Immunohistochemistry with TMA was performed to detect HCC1/CAPERα expression in NSCLC and adjacent lung tissues. NSCLC cell line constitutively transfected by pcDNA3.1-HCC1/CAPERα, and empty pcDNA3.1 vector were used. These cells were analyzed by Western blot, MTT, immunofluorescence, wound healing assay, and transwell assays. It was found that HCC1/CAPERα was mainly localized in the nucleus of the lung cancer cells and overexpression of HCC1/CAPERα may promote lung cancer cells proliferation and increase cells migration. The frequency of HCC1/CAPERα expression in NSCLC tissues was significantly higher than that in adjacent and normal tissues (P < 0.01). Our data suggest that overexpression of HCC1/CAPERα may increase the proliferation and migration of NSCLC cells, and HCC1/CAPERα could be a promising biomarker for lung cancer.
Literature
1.
2.
3.
Zhang JY, Tan EM. Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn. 2010;10:321–8.PubMedCentralCrossRefPubMed
4.
Soussi T. P53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000;60:1777–88.PubMed
5.
Looi K, Megliorino R, Shi FD, Peng XX, Chen Y, Zhang JY. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Onco Rep. 2006;16:1105–10.
6.
Zhang JY, Chan EK, Peng XX, Lu M, Wang X, Mueller F, et al. Autoimmune responses to mRNA binding proteins p62 and koc in diverse malignancies. Clin Immunol. 2001;100:149–56.CrossRefPubMed
7.
Zhang JY, Chan EK, Peng XX, Tan EM. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med. 1999;189:1101–10.PubMedCentralCrossRefPubMed
8.
Soo Hoo L, Zhang JY, Chan EK. Cloning and characterization of a novel 90 kda 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene. 2002;21:5006–15.CrossRefPubMed
9.
10.
Valcarcel J, Gaur RK, Singh R, Green MR. Interaction of u2af65 rs region with pre-mrna branch point and promotion of base pairing with u2 snRNA [corrected]. Science. 1996;273:1706–9.CrossRefPubMed
11.
12.
Jung DJ, Na SY, Na DS, Lee JW. Molecular cloning and characterization of caper, a novel coactivator of activating protein-1 and estrogen receptors. J Biol Chem. 2002;277:1229–34.CrossRefPubMed
13.
Dowhan DH, Hong EP, Auboeuf D, Dennis AP, Wilson MM, Berget SM, et al. Steroid hormone receptor coactivation and alternative RNA splicing by u2af65-related proteins caperalpha and caperbeta. Mol Cell. 2005;17:429–39.CrossRefPubMed
14.
Dutta J, Fan G, Gelinas C. Caperalpha is a novel rel-tad-interacting factor that inhibits lymphocyte transformation by the potent rel/nf-kappab oncoprotein v-rel. J Virol. 2008;82:10792–802.PubMedCentralCrossRefPubMed
15.
Imai H, Chan EK, Kiyosawa K, Fu XD, Tan EM. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest. 1993;92:2419–26.PubMedCentralCrossRefPubMed
16.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
17.
18.
Bangur CS, Switzer A, Fan L, Marton MJ, Meyer MR, Wang T. Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis. Oncogene. 2002;21:3814–25.CrossRefPubMed
19.
Mercier I, Casimiro MC, Zhou J, Wang C, Plymire C, Bryant KG, et al. Genetic ablation of caveolin-1 drives estrogen-hypersensitivity and the development of dcis-like mammary lesions. Am J Pathol. 2009;174:1172–90.PubMedCentralCrossRefPubMed
20.
Chen Y, Zhou Y, Qiu S, Wang K, Liu S, Peng XX, et al. Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett. 2010;289:32–9.PubMedCentralCrossRefPubMed
21.
Shao Q, Ren P, Li Y, Peng B, Dai L, Lei N, et al. Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma. Int J Oncol. 2012;41:1061–7.PubMedCentralPubMed
22.
Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc. 2007;2:329–33.CrossRefPubMed
23.
Liu X, Chai Y, Li J, Ren P, Liu M, Dai L, et al. Autoantibody response to a novel tumor-associated antigen p90/cip2a in breast cancer immunodiagnosis. Tumor Biol. 2014. doi:10.​1007/​s13277-013-1350-6.
24.
Tan EM, Chan EK, Sullivan KF, Rubin RL. Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity. Clin Immunol Immunopathol. 1988;47:121–41.CrossRefPubMed
25.
26.
27.
Nagai K, Oubridge C, Jessen TH, Li J, Evans PR. Crystal structure of the RNA-binding domain of the u1 small nuclear ribonucleoprotein a. Nature. 1990;348:515–20.CrossRefPubMed
28.
Query CC, Bentley RC, Keene JD. A common RNA recognition motif identified within a defined u1 RNA binding domain of the 70 k u1 snrnp protein. Cell. 1989;57:89–101.CrossRefPubMed
29.
30.
Sanford JR, Ellis J, Caceres JF. Multiple roles of arginine/serine-rich splicing factors in RNA processing. Biochem Soc Trans. 2005;33:443–6.CrossRefPubMed
31.
Wan L, Kim JK, Pollard VW, Dreyfuss G. Mutational definition of RNA-binding and protein–protein interaction domains of heterogeneous nuclear rnp c1. J Biol Chem. 2001;276:7681–8.CrossRefPubMed
32.
Scherly D, Dathan NA, Boelens W, van Venrooij WJ, Mattaj IW. The u2b'' rnp motif as a site of protein–protein interaction. EMBO J. 1990;9:3675–81.PubMedCentralPubMed
33.
Shen H, Green MR. A pathway of sequential arginine–serine-rich domain-splicing signal interactions during mammalian spliceosome assembly. Mol Cell. 2004;16:363–73.CrossRefPubMed
34.
Ellis JD, Lleres D, Denegri M, Lamond AI, Caceres JF. Spatial mapping of splicing factor complexes involved in exon and intron definition. J Cell Biol. 2008;181:921–34.PubMedCentralCrossRefPubMed
35.
Stadler C, Rexhepaj E, Singan VR, Murphy RF, Pepperkok R, Uhlen M, et al. Immunofluorescence and fluorescent-protein tagging show high correlation for protein localization in mammalian cells. Nat Methods. 2013;10:315–23.CrossRefPubMed
36.
Metadata
Title
Overexpression of HCC1/CAPERα may play a role in lung cancer carcinogenesis
Authors
Yurong Chai
Xinxin Liu
Liping Dai
Yang Li
Mei Liu
Jian-Ying Zhang
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1819-y

Other articles of this Issue 7/2014

Tumor Biology 7/2014 Go to the issue

Research Article

Genetic variants of NQO1 gene increase bladder cancer risk in Indian population and meta-analysis

Research Article

Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain

Research Article

Significant association between interleukin-17A polymorphism and colorectal cancer

Research Article

XPD Lys751Gln polymorphism is not associated with oral cancer risk: evidence from a meta-analysis

Research Article

Bladder cancer invasion predictability based on preoperative neutrophil–lymphocyte ratio

Research Article

Diagnostic accuracy of contrast-enhanced ultrasound for renal cell carcinoma: a meta-analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits